NCT07396987 Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation
| NCT ID | NCT07396987 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Juan Carlos Cardet |
| Condition | Asthma Attack |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-07-19 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-07-19 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is testing a new way to help adults with asthma get follow up care after an emergency room (ER) visit for an asthma attack. Many people who come to the ER for asthma never see an asthma specialist afterward, even though specialists can offer treatments such as advanced inhalers or biologic medicines that may prevent future attacks. The study will compare two approaches. One group will receive a telehealth appointment with an asthma specialist that is scheduled for them before they leave the ER. The other group will receive the usual care, which typically includes a standard referral but no scheduled appointment. All participants will be offered a prescription for standard controller medication at discharge. The main question the study aims to answer is whether arranging a telehealth visit directly from the ER increases the number of patients who complete a follow up appointment with an asthma specialist within three months. The study will also look at whether this approach improves asthma control, reduces repeat ER visits, and helps patients better understand and use their asthma medications. This research may help identify a practical way to improve access to asthma specialists and reduce the burden of asthma for patients who frequently rely on emergency care.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Asthma diagnosis ≥1 year * Seen in ER for asthma exacerbation * Persistent asthma on controller therapy * ≥1 asthma exacerbation in prior year Exclusion Criteria: * Patients who have seen an asthma specialist (allergist or pulmonologist) for asthma in the past 1 year * Diagnosis of other pulmonary diseases (e.g., COPD, interstitial lung disease, etc.) We will allow for current smokers, vapers and cannabis users as long as they meet one of the COPD-allowable pathways below. COPD-allowable pathways: If none of the below are satisfied, then exclude for COPD. Documentation: PFTs must be within 36 months of enrollment date; smoking history must be calculated and entered in this form based on patient input. Pack- year history will be collected for characterization/analysis but will not determineeligibility. We will allow for COPD as long as they are: * never smokers/vapers/cannabis users; * former or current smokers/vapers/cannabis users with normal PFTs with FEV1/FVC \>=70% documented in a medical record within 36 months of the enrollment date * former or current smoker/vapers/cannabis users with obstruction noted on PFTs (i.e., FEV1/FVC \<70%) but who demonstrates BOTH acute bronchodilator reversibility (i.e., \>10% increase in either FEV1%predicted or FVC% predicted) AND have a normal diffusing capacity (DLCO)
Contact & Investigator
Juan C Cardet, MD
PRINCIPAL INVESTIGATOR
University of South Florida
Frequently Asked Questions
Who can join the NCT07396987 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Asthma Attack. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07396987 currently recruiting?
Yes, NCT07396987 is actively recruiting participants. Contact the research team at Alett1@usf.edu for enrollment information.
Where is the NCT07396987 trial being conducted?
This trial is being conducted at Tampa, United States.
Who is sponsoring the NCT07396987 clinical trial?
NCT07396987 is sponsored by Juan Carlos Cardet. The principal investigator is Juan C Cardet, MD at University of South Florida. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.